Compare TransMedics Group Inc (TMDX) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? TransMedics Group Inc trades at $79.01 (market cap $2.74B), while Vanguard Total World Stock Index Fund ETF trades at $159.46 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 37.1× TransMedics Group Inc's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| TMDX | VT | |
|---|---|---|
Market Cap | $2.74B | $101.70B |
Volume | 949,331 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $150.42 | $162.39 |
52-Week Low | $61.99 | $134.19 |
Typical Hold Time | 24 Days | 53 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
VT trades at $159.64, down 0.66% on the day, with technical indicators showing a bullish bias in moving averages while oscillators remain neutral. The ETF maintains strong global diversification with over 9,700 stocks across developed and emerging markets. Recent news highlights VT's competitive positioning against international-focused ETFs, with Seeking Alpha maintaining a Buy rating and targeting 6-10% returns over the next 6-12 months.
VT offers comprehensive global equity exposure with a low 0.06% expense ratio, though key financial ratios remain unavailable. The outlook remains positive for long-term diversification, with risks including currency fluctuations and geopolitical tensions. Institutional activity shows mixed signals with both position increases and decreases reported in recent quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
